Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Name: Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Published: 2023
License: Public Domain

Academic and Community Cancer Research United · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

metastatic colon adenocarcinoma, metastatic colorectal adenocarcinoma, metastatic rectal adenocarcinoma, stage iv colon cancer ajcc v8, stage iv colorectal cancer ajcc v8, stage iv rectal cancer ajcc v8, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Related documents